Axi Select Celebrates Top Milestone: Trader Secures $1,000,000 in Capital Funding

AXI SELECT CELEBRATES TOP MILESTONE: TRADER SECURES $1,000,000 IN CAPITAL FUNDING AXI SELECT CELEBRATES TOP MILESTONE: TRADER SECURES $1,000,000 IN CAPITAL FUNDING SYDNEY, Feb. 20, 2025 (GLOBE NEWSWIRE) — Axi, a leading global provider of online trading services, has proudly announced that trader Francisco Quesada Godines has reached the top milestone in its innovative capital […]

Read More »

GN introduces its most intelligent hearing portfolio yet, including ReSound Vivia – the world’s smallest AI powered hearing aid

ReSound Vivia Built on decades of shared AI research and development across the GN Group, GN has pioneered a unique approach to AI that mimics the brain’s natural sound processing via a new Intelligent Focus feature to create a superior hearing experience in noise. This breakthrough technology is packed in the world’s smallest rechargeable Receiver-in-Ear […]

Read More »

Beltone Debuts Latest Hearing Innovations with Beltone Envision(TM) Hearing Aids –The World’s Best Technology for Hearing in Noise And New Auracast Assistant

Designed with intelligent hearing technology, Beltone Envision AI powered hearing aids are compact yet powerful, helping individuals with hearing loss focus on hearing what matters most, even in challenging listening situations BALLERUP, Denmark, Feb. 04, 2025 (GLOBE NEWSWIRE) — Beltone proudly introduces its latest innovation: Beltone Envision™ hearing aids. Featuring the world’s best technology for hearing in noise1, […]

Read More »

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for future milestone-dependent payments and royalties, while retaining rights to commercialize CV-01 in the Republic of […]

Read More »

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T Builds on long-standing relationship between the two companies In Japan around 90,000 new cases of prostate cancer are diagnosed each year PARIS, Oct. 01, 2024 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced today that it has entered […]

Read More »